Transition complete
Executive Summary
Former Warner-Lambert Global Pharmaceutical President Anthony Wild, PhD, has formed a specialty pharmaceutical investment fund, MedPointe Capital Partners. Wild was one of the top-ranking Warner-Lambert executives on the transition team following the Pfizer merger. Wild has also joined the Allergan board of directors, replacing former SmithKline Beecham Chairman Henry Wendt